Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

609

Shown on this page

Current sort

Live official records

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: REGN5678, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 24
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Menstrual Migraine
Interventions: Rimegepant, Placebo Comparator, Standard of Care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 32
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Canoga Park, California + 25 more

Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions: (Z)-endoxifen, goserelin; Drug
Lead sponsor: Atossa Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Advanced Malignant Solid Neoplasm, Malignant Brain Neoplasm, Recurrent Advanced Malignant Solid Neoplasm
Interventions: Advance Care Planning, Educational Intervention, Electronic Health Record Review, Survey Administration; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 39 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Biochemically Recurrent Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 25
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more

Conditions: Moderate Aortic Valve Stenosis
Interventions: Ataciguat, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 61 more

Conditions: Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions: ALE.P03; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more

Conditions: Leukemia
Interventions: Quizartinib, Placebo, Chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 52
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1403
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more

Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside; Drug · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 90
States / cities: Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more

Conditions: Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Live official records

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors

Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

About this Mayo Clinic institution page